<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674358</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-DED-019</org_study_id>
    <nct_id>NCT04674358</nct_id>
  </id_info>
  <brief_title>The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease</brief_title>
  <official_title>The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design,&#xD;
      Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25%&#xD;
      Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conjunctival redness assessed over 90 minutes in the dry eye chamber.</measure>
    <time_frame>Day 2.</time_frame>
    <description>Ora CalibraÂ® Conjunctival Redness Scale for Dry Eye (0 = Normal, 4 = Severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tear RASP (reactive aldehyde species) levels.</measure>
    <time_frame>Day 1 and 2.</time_frame>
    <description>Tear levels of RASP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's Test</measure>
    <time_frame>Day 1.</time_frame>
    <description>Measured using a sterile Schirmer's Test Strip.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Dry Eye</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution administered over two consecutive days.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%)</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Opthalmic Solution</intervention_name>
    <description>Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).</description>
    <arm_group_label>Vehicle Ophthalmic Solution administered over two consecutive days.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age (either gender and any race);&#xD;
&#xD;
          -  Reported history of dry eye for at least 6 months prior to Visit 1;&#xD;
&#xD;
          -  Reported history of use or desire to use eye drops for dry eye symptoms within 6&#xD;
             months of Visit 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant slit lamp findings at Visit 1 that may include active&#xD;
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active&#xD;
             ocular allergies that require therapeutic treatment, and/or in the opinion of the&#xD;
             investigator may interfere with study parameters;&#xD;
&#xD;
          -  Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active&#xD;
             ocular inflammation at Visit 1;&#xD;
&#xD;
          -  Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during&#xD;
             the trial;&#xD;
&#xD;
          -  Eye drop use within 2 hours of Visit 1;&#xD;
&#xD;
          -  Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12&#xD;
             months;&#xD;
&#xD;
          -  Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution use within 90 days&#xD;
             of Visit 1;&#xD;
&#xD;
          -  Be receiving systemic corticosteroid therapy (not including inhaled corticosteroids)&#xD;
             within 14 days of Visit 1 or anticipate such therapy throughout the study period;&#xD;
&#xD;
          -  Planned ocular and/or lid surgeries over the study period or any ocular surgery within&#xD;
             6 months of Visit 1;&#xD;
&#xD;
          -  Temporary punctal plugs during the study that have not been stable within 30 days of&#xD;
             Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bill Cavanagh</last_name>
    <phone>781-257-3063</phone>
    <email>bcavanagh@aldeyra.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Gow, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Health</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian M. Jerkins, MD</last_name>
      <phone>901-448-6650</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reproxalap</keyword>
  <keyword>ADX-102</keyword>
  <keyword>Tranquility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

